OOIR: Observatory of International Research

Papers

(The H4-Index of CTS-Clinical and Translational Science is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Issue Information	79
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	75
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	71
Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets	65
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	61
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	59
Intradermal substance P as a challenge agent in healthy individuals	59
Using partition analysis as a facile method to derive net clearances	59
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	50
Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?	47
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	43
Pharmacogenomic landscape of Indian population using whole genomes	39
Expanding regulatory science: Regulatory complementarity and reliance	37
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	36
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	36
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	36
Issue Information	31
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	31
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	30
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	30
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	29
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	29
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	29
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	29
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	28

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	27
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	27
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue	27
Generalizability in real‐world trials	27